Search Results - "VOSE, Julie"

Mantle cell lymphoma: 2017 update on diagnosis, risk‐stratification, and clinical management by Vose, Julie M.

“…Disease Overview Mantle cell lymphoma (MCL) is a non‐Hodgkin lymphoma characterized by involvement of the lymph nodes, spleen, blood and bone marrow with a…”
Get full text

To transplant or not to transplant: that is the question in PTCL by Vose, Julie M.

Get full text

Delay in Cancer Screening and Diagnosis During the COVID-19 Pandemic: What Is the Cost? by Vose, Julie M

“…During the height of the coronavirus disease 2019(COVID-19) pandemic, many health care facilities needed to focus on screening for and treating patients with…”
Get more information

Mantle cell lymphoma: 2015 update on diagnosis, risk‐stratification, and clinical management by Vose, Julie M.

“…Disease Overview: Mantle cell lymphoma (MCL) is a non‐Hodgkin lymphoma characterized by involvement of the lymph nodes, spleen, blood and bone marrow with a…”
Get full text

Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma by Lunning, Matthew A., Vose, Julie M.

“…Angioimmunoblastic T-cell lymphoma (AITL) is an uncommon subtype of mature peripheral T-cell lymphoma (PTCL). The history of AITL is much longer and deeper…”
Get full text

Outcomes for PTCL: which pathway to success? by Vose, Julie M.

Get full text

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results by Advani, Ranjana H., Moskowitz, Alison J., Bartlett, Nancy L., Vose, Julie M., Ramchandren, Radhakrishnan, Feldman, Tatyana A., LaCasce, Ann S., Christian, Beth A., Ansell, Stephen M., Moskowitz, Craig H., Brown, Lisa, Zhang, Chiyu, Taft, David, Ansari, Sahar, Sacchi, Mariana, Ho, Linda, Herrera, Alex F.

“…This phase 1-2 study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo) as first salvage therapy in patients with relapsed/refractory (r/r)…”
Get full text

Mantle cell lymphoma: 2013 Update on diagnosis, risk‐stratification, and clinical management by Vose, Julie M.

“…Disease Overview Mantle cell lymphoma (MCL) is a non‐Hodgkin lymphoma characterized by involvement of the lymph nodes, spleen, blood, and bone marrow with a…”
Get full text

A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T‐cell lymphoma (PTCL): final results from the T‐ cell consortium trial by Advani, Ranjana H., Ansell, Stephen M., Lechowicz, Mary J., Beaven, Anne W., Loberiza, Fausto, Carson, Kenneth R., Evens, Andrew M., Foss, Francine, Horwitz, Steven, Pro, Barbara, Pinter‐Brown, Lauren C., Smith, Sonali M., Shustov, Andrei R., Savage, Kerry J., M. Vose, Julie

“…Summary Peripheral T‐cell lymphomas (PTCL) have suboptimal outcomes using conventional CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)…”
Get full text

International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes by Vose, Julie, Armitage, James, Weisenburger, Dennis

“…Peripheral T-cell lymphoma (PTCL) and natural killer/T-cell lymphoma (NKTCL) are rare and heterogeneous forms of non-Hodgkin's lymphoma (NHL) that, in general,…”
Get full text

Addressing Stress and Burnout in Hematology/Oncology Physicians by Vose, Julie

Get more information

Chemoimmunotherapy for localised low-risk diffuse large B-cell lymphoma by Vose, Julie M

“…In previous clinical trials, patients with localised stage I or II diffuse large B-cell lymphoma who were younger than 60 years without risk factors such as…”
Get full text

Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management by Vose, Julie M.

“…Disease Overview: Mantle cell lymphoma (MCL) is a non‐Hodgkin lymphoma characterized by involvement of the lymph nodes, spleen, blood, and bone marrow with a…”
Get full text

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium by Nastoupil, Loretta J, Jain, Michael D, Feng, Lei, Spiegel, Jay Y, Ghobadi, Armin, Lin, Yi, Dahiya, Saurabh, Lunning, Matthew, Lekakis, Lazaros, Reagan, Patrick, Oluwole, Olalekan, McGuirk, Joseph, Deol, Abhinav, Sehgal, Alison R, Goy, Andre, Hill, Brian T, Vu, Khoan, Andreadis, Charalambos, Munoz, Javier, Westin, Jason, Chavez, Julio C, Cashen, Amanda, Bennani, N Nora, Rapoport, Aaron P, Vose, Julie M, Miklos, David B, Neelapu, Sattva S, Locke, Frederick L

“…Axicabtagene ciloleucel (axi-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory large B-cell…”
Get full text

Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received by Schnipper, Lowell E, Davidson, Nancy E, Wollins, Dana S, Blayney, Douglas W, Dicker, Adam P, Ganz, Patricia A, Hoverman, J Russell, Langdon, Robert, Lyman, Gary H, Meropol, Neal J, Mulvey, Therese, Newcomer, Lee, Peppercorn, Jeffrey, Polite, Blase, Raghavan, Derek, Rossi, Gregory, Saltz, Leonard, Schrag, Deborah, Smith, Thomas J, Yu, Peter P, Hudis, Clifford A, Vose, Julie M, Schilsky, Richard L

Get full text

Peripheral T-cell lymphoma: novel backbone by Vose, Julie M.

Get full text

Fighting 2 Enemies: Cancer and COVID-19 by Vose, Julie M

Get more information

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma by Herrera, Alex F., Moskowitz, Alison J., Bartlett, Nancy L., Vose, Julie M., Ramchandren, Radhakrishnan, Feldman, Tatyana A., LaCasce, Ann S., Ansell, Stephen M., Moskowitz, Craig H., Fenton, Keenan, Ogden, Carol Anne, Taft, David, Zhang, Qu, Kato, Kazunobu, Campbell, Mary, Advani, Ranjana H.

“…In this phase 1/2 study, brentuximab vedotin (BV) and nivolumab (Nivo) administered in combination were evaluated as initial salvage therapy in patients with…”
Get full text

Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma by Kallam, Avyakta, Vose, Julie M.

“…Adoptive cellular immunotherapy with anti CD19 chimeric antigen receptor (CAR)-T cell has changed the treatment landscape in relapsed/refractory B cell…”
Get full text

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma by Wilson, Wyndham H, Young, Ryan M, Schmitz, Roland, Yang, Yandan, Pittaluga, Stefania, Wright, George, Lih, Chih-Jian, Williams, P Mickey, Shaffer, Arthur L, Gerecitano, John, de Vos, Sven, Goy, Andre, Kenkre, Vaishalee P, Barr, Paul M, Blum, Kristie A, Shustov, Andrei, Advani, Ranjana, Fowler, Nathan H, Vose, Julie M, Elstrom, Rebecca L, Habermann, Thomas M, Barrientos, Jacqueline C, McGreivy, Jesse, Fardis, Maria, Chang, Betty Y, Clow, Fong, Munneke, Brian, Moussa, Davina, Beaupre, Darrin M, Staudt, Louis M

“…Clinical testing of BCR inhibition on DLBCL reveals determinants of response. The two major subtypes of diffuse large B cell lymphoma (DLBCL)—activated B…”
Get full text